BRUKER CORP 8-K

What Happened

• On January 12, 2026, Bruker Corporation announced at the J.P. Morgan Healthcare Conference preliminary results for the quarter ended December 31, 2025 and a preliminary outlook for fiscal 2026. The company stated Q4 2025 revenue is expected to be between $965 million and $970 million, and that its Bruker Scientific Instruments segments had a book-to-bill ratio above 1.0. Bruker also provided a preliminary 2026 outlook calling for organic revenue growth of flat to up low-single digits, non-GAAP organic operating margin expansion of 250–300 basis points, and non-GAAP EPS growth in the double-digits versus full year 2025.

Key Details

• Q4 2025 preliminary revenue: $965M–$970M.
• Bruker Scientific Instruments book-to-bill: above 1.0 for Q4 2025.
• 2026 preliminary outlook vs. 2025: organic revenue flat to up low-single digits; non-GAAP organic operating margins +250–300 bps; non-GAAP EPS double-digit growth.
• Announcement made Jan 12, 2026; presentation available in Investors section at ir.bruker.com. Company noted these are preliminary, unaudited estimates and subject to change.

Why It Matters

• These preliminary figures give investors an early look at Bruker’s recent revenue performance and management’s expectations for margin improvement and EPS growth in 2026. The above-1.0 book-to-bill in its scientific instruments segment suggests order demand exceeded shipments in Q4. However, results are unaudited and final 2025 financials may differ materially, so investors should await the completed financial statements before drawing firm conclusions.